siRNAgen Therapeutics offers a comprehensive, end-to-end RNAi drug development service, covering candidate sequence design, synthesis, and both in vitro and in vivo efficacy evaluation.
All data are generated in strict compliance with MIQE guidelines to ensure reliability and transparency, while automated high-throughput screening systems enable efficient and large-scale sample processing.
Leveraging extensive expertise in siRNA drug development, siRNAgen Therapeutics delivers customized candidate selection and provides clients with detailed experimental reports.

1. Reliable results with MIQE guidelines

The MIQE (Minimum Information for Publication of Quantitative Real-Time PCR Experiments) guidelines establish the essential standards and information required for the accurate and reliable reporting of quantitative real-time PCR experiments.
All experimental procedures and data analyses in this RNAi High-throughput screening service are conducted in strict accordance with these guidelines.
By adhering to internationally recognized MIQE standards, the objectivity and reliability of the results are greatly enhanced, ensuring that the generated data are suitable for scientific publication.

2. High-throughput screening

High-throughput screening is conducted using the ExiPrep™ 96 Lite automated nucleic acid extraction system and the Exicycler™ 384 real-time quantitative thermal block for 384-well RT-qPCR.
The integration of these automated systems ensures high operational efficiency and supports large-scale sample processing.

3. End-to-End solution

By conducting synthesis as well as both in vitro and in vivo efficacy evaluations in one place, you can significantly reduce both time and costs.

4. Expertise in siRNA Drug Development

We possess extensive know-how in siRNA drug development, ensuring reliable and effective research outcomes.